Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia

M Miller; C Dolinar; W Cromwell; J D Otvos

doi:10.1016/s0002-9149(00)01327-8

Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia

Am J Cardiol. 2001 Jan 15;87(2):232-4, A9. doi: 10.1016/s0002-9149(00)01327-8.

Authors

M Miller¹, C Dolinar, W Cromwell, J D Otvos

Affiliation

¹ Division of Cardiology, University of Maryland Medical Center, Baltimore, USA. mmiller@heart.umaryland.edu

PMID: 11152850
DOI: 10.1016/s0002-9149(00)01327-8

Abstract

Twenty subjects with mixed hyperlipidemia participated in a 3-arm crossover trial to evaluate the effectiveness of high-dose simvastatin as monotherapy. Significant reductions were observed in atherogenic lipids and lipoproteins. The highest dose of simvastatin also resulted in significant increases in high-density lipoprotein cholesterol (21%) with a comparable increase in large, protective high-density lipoprotein particles.

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Drug Administration Schedule
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipidemias / drug therapy*
Hypolipidemic Agents / administration & dosage*
Hypolipidemic Agents / therapeutic use
Lipids / blood
Magnetic Resonance Spectroscopy
Simvastatin / administration & dosage*
Simvastatin / therapeutic use

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipids
Simvastatin